SCM
NEUP

Squadron Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Squadron Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-76,728
Closed -$312K – 59
2026
Q1 		$312K Buy
+76,728
New +$324K 0.11% 37

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Squadron Capital Management's NEUP Position: Q2 2026 in Review

Squadron Capital Management sold out of Neuphoria Therapeutics (NEUP) in Q2 2026, closing a stake of 76,728 shares — an estimated $312K sold.

Squadron Capital Management first reported a position in NEUP in Q1 2026 and held it in 1 quarter. The position peaked at $312K in Q1 2026. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Squadron Capital Management reported no remaining Neuphoria Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 76,728 Neuphoria Therapeutics shares in Q2 2026, an estimated $312K.
  • Squadron Capital Management first reported a position in Neuphoria Therapeutics in Q1 2026 and held it in 1 quarter.
  • Squadron Capital Management's Neuphoria Therapeutics position peaked at $312K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.